The present study involves the structure–function relationship between MUC4EGF domains and HER2 at the molecular level and their biological activity on human pancreatic cancer cells, confirming the potency for developing small inhibitory molecules targeting MUC4EGF domains with therapeutic value. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.